Evommune Q1 EPS $(0.64) Beats $(0.71) Estimate

Benzinga Newsdesk www.benzinga.com Negative 96.8%

Neg 96.8% Neu 0% Pos 0%

Evommune (NYSE:EVMN) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.71) by 9.86 percent.